<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725881</url>
  </required_header>
  <id_info>
    <org_study_id>DP100-301</org_study_id>
    <nct_id>NCT00725881</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Phase 1/2 Dose-Range-Finding Study to Evaluate the Safety, Efficacy and PK of Multiple Once Daily Intravenous Doses of TSC in Patients With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diffusion Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diffusion Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of multiple,&#xD;
      once-daily, intravenous doses of trans sodium crocetinate (TSC). The effectiveness of TSC in&#xD;
      alleviating the symptoms of intermittent claudication (IC) will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral Artery Disease (PAD) is a manifestation of systemic atherosclerosis, and patients&#xD;
      with PAD commonly manifest symptoms of intermittent claudication (IC) such as cramping,&#xD;
      aching, or fatigue in the calf muscles provoked by activity. In PAD, arterial occlusions lead&#xD;
      to decreased leg blood flow during exercise or walking and the pain associated with this&#xD;
      ischemia is IC. The diffusion of oxygen from blood to muscle could be a component of the&#xD;
      overall decreased delivery or deficit of oxygen (hypoxia) to skeletal muscle resulting in&#xD;
      symptoms in PAD patients. The overall goal of the development of TSC as a treatment for PAD&#xD;
      is to allow for enhanced diffusion of oxygen through the plasma to alleviate the symptoms&#xD;
      caused by the hypoxia in the tissues.&#xD;
&#xD;
      This double-blinded, placebo-controlled clinical trial will randomize up to 48 patients at up&#xD;
      to 8 clinical research sites in the US. In addition to safety and pharmacokinetic assessments&#xD;
      conducted during the trial, the primary endpoint of the study will be demonstrated from&#xD;
      standardized, graded exercise treadmill tests conducted throughout the study. The clearly&#xD;
      measurable parameters will be peak walking time (PWT) and claudication onset time (COT)&#xD;
      comparing baseline and after TSC or placebo and are well-established endpoints accepted by&#xD;
      the medical community and regulatory authorities for IC clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (laboratory tests, vital signs, ECG, physical exam, pulse oximetry) and pharmacokinetic assessments</measure>
    <time_frame>Screening, Baseline, Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, 5-Day Follow-up, 14-Day Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak walking time (PWT) and claudication onset time (COT) in an exercise treadmill test</measure>
    <time_frame>Baseline, Dose 1, Dose 5, 5-Day Follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.25 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.5 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.75 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.75 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg/kg TSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5.0 mL 0.9% normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans sodium crocetinate (TSC)</intervention_name>
    <description>Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% normal saline</intervention_name>
    <description>A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40 or older, male or female&#xD;
&#xD;
          -  6-mo. history of walking limitation or symptoms of intermittent claudication (IC) in&#xD;
             at least 1 lower limb, severity of which has not changed in the past 3 mo. and&#xD;
             diagnosed by principal investigator as clinically stable Fontaine Stage II peripheral&#xD;
             artery disease (PAD)&#xD;
&#xD;
          -  Diagnosis of PAD secondary to atherosclerosis&#xD;
&#xD;
          -  If ankle-brachial index (ABI) is &gt; 1.3 or cannot be measured in either leg, vascular&#xD;
             etiology documented by toe-brachial index (TBI) â‰¤ 0.7 in at least 1 leg&#xD;
&#xD;
          -  Claudication severity, meds. for the treatment of coronary artery disease (CAD), PAD&#xD;
             and IC, and exercise habits should be clinically stable for 3 mo. prior to Screening&#xD;
             (SCRN) and during study. Pt. is not likely to change smoking and/or exercise habits&#xD;
             during study&#xD;
&#xD;
          -  On an exercise treadmill test (ETT), peak walking time (PWT) of at least 1 min., but&#xD;
             no more than 12 min. at Baseline&#xD;
&#xD;
          -  Willing and able to discontinue Pletal or Trental for 21 days before SCRN and during&#xD;
             study&#xD;
&#xD;
          -  Antihypertensive therapy, cholesterol-lowering therapy, chronic oral nitrates, and&#xD;
             diabetic therapy have been stable for 30 days prior to SCRN&#xD;
&#xD;
          -  Willing and able to provide written, signed, informed consent after the nature of the&#xD;
             study has been explained and prior to any research-related procedures&#xD;
&#xD;
          -  Willing and able to comply with all study-related procedures&#xD;
&#xD;
          -  Sexually active patients must use an acceptable method of contraception while&#xD;
             participating in the study&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test at SCRN and have&#xD;
             additional pregnancy tests during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Current or history of critical limb ischemia (CLI)&#xD;
&#xD;
          -  Pts. in whom artery insufficiency in the lower extremity is the result of acute limb&#xD;
             ischemia (ALI) or an immunological or inflammatory non-atherosclerotic disorder&#xD;
&#xD;
          -  Pts. in whom walking impairment due to pain is the result of other non-atherosclerotic&#xD;
             co-morbid conditions&#xD;
&#xD;
          -  A surgical intervention to alleviate symptoms of IC or PAD-specific endovascular&#xD;
             intervention or cardiovascular surgery within 3 mo. of SCRN&#xD;
&#xD;
          -  Walking limited by reasons other than claudication&#xD;
&#xD;
          -  Conditions other than IC of significant severity that could confound PWT on the ETT&#xD;
&#xD;
          -  Concurrent severe congestive heart failure (CHF)&#xD;
&#xD;
          -  Life-threatening ventricular arrhythmias, unstable angina, and/or myocardial&#xD;
             infarction (MI) within 3 mo. before enrollment (ENRL)&#xD;
&#xD;
          -  Coronary artery bypass grafting or percutaneous coronary intervention within 4 mo.&#xD;
             before ENRL&#xD;
&#xD;
          -  Renal and/or carotid revascularization procedure within 3 mo. of ENRL&#xD;
&#xD;
          -  Transient ischemic attack (TIA) within 3 mo. before ENRL&#xD;
&#xD;
          -  Deep vein thrombosis (DVT) within 3 mo. before ENRL&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Thrombocytopenia&#xD;
&#xD;
          -  Undergoing hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Pts. w/immunocompromised conditions, organ transplant recipients and/or need for&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Neurological dementia&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Clinically significant electrocardiogram (ECG) change during or after ETT at SCRN or&#xD;
             Baseline visit(s)&#xD;
&#xD;
          -  Cerebrovascular infarct within 3 mo. of SCRN&#xD;
&#xD;
          -  Poorly controlled type 1 or type 2 diabetes at SCRN&#xD;
&#xD;
          -  History of migraine headaches within last 12 mo.&#xD;
&#xD;
          -  Patients with clinically significant abnormal hematology labs or blood chemistry labs&#xD;
&#xD;
          -  Body mass index &gt; 35&#xD;
&#xD;
          -  Hypertension at SCRN defined as resting BP values of &gt; 170 mmHg systolic and/or &gt; 110&#xD;
             mmHg diastolic&#xD;
&#xD;
          -  Hypotension at SCRN defined as resting BP values &lt; 100 mmHg systolic or &lt; 55 mmHg&#xD;
             diastolic or symptomatic hypotension&#xD;
&#xD;
          -  Previous treatment with any formulation of TSC&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any excipient (gamma-cyclodextrin, mannitol,&#xD;
             glycine) of TSC formulation&#xD;
&#xD;
          -  Previous treatment with gene therapy or other VEGF-related treatment within 12 mo. of&#xD;
             SCRN&#xD;
&#xD;
          -  Patients with recent history of alcoholism or drug abuse, or severe emotional,&#xD;
             behavioral, or psychiatric problems&#xD;
&#xD;
          -  Patients receiving experimental medications or participating in other study using an&#xD;
             experimental drug or procedure within 45 days prior to ENRL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine, Division of Cardiovascular Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrews Research and Education</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <disposition_first_submitted>June 14, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 29, 2011</disposition_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kim M. Whitten, PharmD, RAC</name_title>
    <organization>Diffusion Pharmaceuticals LLC</organization>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>Peripheral artery disease</keyword>
  <keyword>Intermittent claudication</keyword>
  <keyword>IC</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>leg pain</keyword>
  <keyword>walking pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trans-sodium crocetinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

